Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

PURPOSE: Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma. EXPERIMENTAL DESIGN: A panel of 116 small m...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662464/
https://www.ncbi.nlm.nih.gov/pubmed/26254279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662464/
https://www.ncbi.nlm.nih.gov/pubmed/26254279

Ejemplares similares